Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10868MR)

This product GTTS-WQ10868MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Melanoma, Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10868MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7961MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ3649MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ10222MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ4555MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ4546MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ12789MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ7996MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ4301MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB-054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW